IN FIRST-LINE LOW-GRADE LYMPHOMA PATIENTS WHO DID NOT PROGRESS FOLLOWING CVP

ECOG 1496: RITUXAN POST-INDUCTION THERAPY REDUCED THE RISK OF PROGRESSION, RELAPSE, OR DEATH BY 51% 1

  • The risk of progression, relapse, or death doubled (2.04x) for patients in the observation arm*

*The risk of progression, relapse, or death for the observation arm of the ECOG 1496 trial was calculated using the formula 1/HR.

SELECT IMPORTANT SAFETY INFORMATION

SINGLE-AGENT RITUXAN FOR LOW-GRADE NHL AFTER FIRST-LINE CVP CHEMOTHERAPY

  • Neutropenia was the only Grade 3 or 4 adverse reaction that occurred more frequently (≥2%) in the RITUXAN arm compared with those who received no further therapy (4% vs. 1%)
  • The following common adverse reactions were reported more frequently (≥5%) in patients receiving RITUXAN following CVP compared with those who received no further therapy: fatigue (39% vs. 14%), anemia (35% vs. 20%), peripheral sensory neuropathy (30% vs. 18%), infections (19% vs. 9%), pulmonary toxicity (18% vs. 10%), hepatobiliary toxicity (17% vs. 7%), rash and/or pruritus (17% vs. 5%), arthralgia (12% vs. 3%), and weight gain (11% vs. 4%)

CVP=cyclophosphamide, vincristine, prednisone; ECOG=Eastern Cooperative Oncology Group; R=RITUXAN; HR=hazard ratio.

NEXT: DOSING AND ADMINISTRATION >

CONTACT YOUR REPRESENTATIVE

Interested in more information about RITUXAN clinical data?